Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24463147 | 0.71 | LMNA (0.35) | KDM4ELMNATSHR | |
| SCHEMBL19911639 | 0.67 | SLC9A1 (0.47) | RAB9ASLC9A1KEAP1POLBKDM4E | |
| SCHEMBL31306003 | 0.66 | LMNA (0.41) | RAB9ASLC9A1KEAP1KDM4ELMNA | |
| SCHEMBL31475796 | 0.66 | KDM4E (0.37) | RAB9ASLC9A1KEAP1POLBKDM4E | |
| SCHEMBL16832061 | 0.66 | LMNA (0.41) | RAB9ASLC9A1KEAP1KDM4ELMNA | |
| SCHEMBL24463608 | 0.65 | BRD4 (0.37) | — | |
| SCHEMBL24463250 | 0.65 | ADORA2A (0.35) | RAB9AKDM4EMAPT | |
| SCHEMBL24463423 | 0.64 | KDM4E (0.38) | RAB9AKDM4ELMNATSHRMAPT | |
| SCHEMBL24463433 | 0.64 | — | — | |
| SCHEMBL18912134 | 0.63 | KEAP1 (0.42) | RAB9ASLC9A1KEAP1POLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116057045-A | Fibroblast growth factor receptor kinase inhibitors | 金耐特生物制药公司 | 2023-05-02 | — | — | CN | disclosed |
| EP-4161656-A1 | INHIBITORS OF FIBROBLAST GROWTH FACTOR RECEPTOR KINASES | Kinnate Biopharma Inc. (US) | 2023-04-12 | — | — | EP | disclosed |
| US-11345681-B1 | Inhibitors of fibroblast growth factor receptor kinases | KINNATE BIOPHARMA INC. (US) | 2022-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345681-B1 | Inhibitors of fibroblast growth factor receptor kinases | FGFR1, FGFR2, FGFR3 | RAB9A 2047/4885SLC9A1 4628/4885KEAP1 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.